Article content
OTTAWA Innovation Minister François-Philippe Champagne says the federal government is acting to ensure intellectual property developed in Canada remains in the country, following longstanding industry concerns about foreign firms capitalizing on domestic research and inventions.
Monday’s budget promised to fund advice for high-growth firms and startups and review IP provisions in Ottawa’s business-support programs. The government has also recently signalled greater scrutiny of foreign investments involving sensitive technologies and research partnerships. “Data and certainly intellectual property are going to be key in the economy of tomorrow,” Champagne said in an interview with
The Logic Wednesday. “I am willing to deploy all the tools that I have in my toolbox to make sure that this is staying in Canada.”
Photo Credit: Stock.adobe
The federal budget has now been released, with $101.4 billion in new spending and a projected deficit of $354.2 billion for 2020 and dropping to $154.7 billion in the current 2021-22 fiscal year.
The focus of the budget is on pandemic recovery and resiliency with spending in three key areas: raising the federal minimum wage, $30 billion towards a national childcare plan, and $17.6 billion towards cleantech investments. It also includes a 50 per cent 10-year reduction on corporate and small business income tax rates for companies manufacturing zero-emissions technologies, such as solar panels and electric buses.
But there is plenty of interest for Canada’s manufacturing sector, although the Canadian Manufacturers & Exporters association found much to criticize.
Federal Budget 2021: Ten key takeaways for the innovation economy thewhig.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewhig.com Daily Mail and Mail on Sunday newspapers.
Key components of Pallister s made-in-Canada vaccine sourced from U.S. and Switzerland
When Premier Brian Pallister plunked down a $7.2-million, non-refundable down payment on a yet-to-be approved COVID-19 vaccine from a tiny Calgary pharmaceutical company, he justified the expense as a way of breaking Canada’s dependency on foreign vaccines.
Social Sharing